Henk R. Franke, M.D., Ph.D., a Peter H. M. van de Weijer, M.D., Ph.D., b Ton M. M. Pennings, M.D., c and Marius J. van der Mooren, M.D., Ph.D.

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Henk R. Franke, M.D., Ph.D., a Peter H. M. van de Weijer, M.D., Ph.D., b Ton M. M. Pennings, M.D., c and Marius J. van der Mooren, M.D., Ph.D."

Transcription

1 FERTILITY AND STERILITY VOL. 74, NO. 3, SEPTEMBER 2000 Copyright 2000 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Gonadotropin-releasing hormone agonist plus add-back hormone replacement therapy for treatment of endometriosis: a prospective, randomized, placebocontrolled, double-blind trial Henk R. Franke, M.D., Ph.D., a Peter H. M. van de Weijer, M.D., Ph.D., b Ton M. M. Pennings, M.D., c and Marius J. van der Mooren, M.D., Ph.D. d Medisch Spectrum Twente Hospital Group, Enschede; ZCA Hospital Center, Apeldoom; Gemini Hospital, Den Helder; and Academic Hospital Vrije Universiteit, Amsterdam, The Netherlands Received November 18, 1999; accepted March 8, Supported by AstraZeneca and Novo Nordisk, who also supplied active drugs and placebo. Reprint requests: Henk R. Franke, M.D., Ph.D., Department of Obstetrics and Gynecology, Medisch Spectrum Twente Hospital Group, P.O. Box 50000, 7500 KA Enschede, The Netherlands (FAX: ; a Department of Obstetrics and Gynecology, Medisch Spectrum Twente Hospital Group, Enschede. b Department of Obstetrics and Gynecology, ZCA Hospital Center, Apeldoorn. c Department of Obstetrics and Gynecology, Gemini Hospital, Den Helder. d Department of Obstetrics and Gynecology, Academic Hospital Vrije Universiteit, Amsterdam /00/$20.00 PII S (00) Objective: To assess the effect of add-back therapy with continuous combined estrogen-progestin on the GnRH agonist induced hypoestrogenic state and its effectiveness in healing of endometriotic lesions. Design: A prospective, randomized, placebo-controlled, double-blind trial. Setting: Multiple centers in The Netherlands. Patient(s): 41 premenopausal women with laparoscopically diagnosed endometriosis (revised American Fertility Society scores 2). Intervention(s): Patients were randomly assigned to receive a subcutaneous depot formulation of goserelin, 3.6 mg, every 4 weeks, plus oral placebo or oral continuous combined estradiol-norethisterone acetate add-back therapy daily for 24 weeks. Main Outcome Measure(s): Endometriosis response, bone mineral density, transvaginal ultrasonographic changes, endocrinologic effects, and subjective side effects. Result(s): The number of endometriotic implants was significantly reduced in both groups. In the group that received GnRH agonist plus placebo, bone mineral density of the lumbar spine decreased by 5.02%. Conclusion(s): The effectiveness of GnRH agonist treatment for endometriosis was not decreased by the addition of add-back continuous combined hormone replacement therapy. Bone mineral density of the lumbar spine was maintained and subjective side effects were diminished. (Fertil Steril 2000;74: by American Society for Reproductive Medicine.) Key Words: Endometriosis, gonadotropin-releasing hormone agonist, add-back, second-look laparoscopy, bone mineral density The exact etiology of endometriosis still remains unknown. In 1921, Sampson (1) suggested that endometriosis develops as a result of menstrual regurgitation and subsequent implantation of endometrial tissue on the peritoneal surface. More recently, genetic and immunologic factors have been proposed (2). Endometriosis is the second most common gynecologic condition, after fibroids. It affects about 10% of all women of reproductive age. Pelvic pain, infertility, dysmenorrhea, abnormal bleeding, dyspareunia, and backache are primarily associated with endometriosis. It has been suggested that the frequency of this disease has increased in recent years, although this is probably the result of greater use of diagnostic laparoscopy and better recognition of the more subtle laparoscopic signs of endometriosis. The benefits of GnRH agonist for treatment of endometriosis are well established (3 9). Continued administration of GnRH agonist desensitizes GnRH receptors of the pituitary gland, which causes an initial stimulation of the pituitary ovarian axis followed by suppression of gonadotropin secretion and hypoestrogenism. Until recently, GnRH agonist administration was limited to 6 months because of con- 534

2 cerns about the long-term impact of the chronic hypoestrogenic state that these agents induce. Adverse effects of GnRH therapy are subjective vasomotor symptoms, such as hot flushes and increased sweating often accompanied by sleeplessness, and objective findings, such as vaginal dryness and loss of bone mineral density. The bone loss induced by GnRH agonist is greater than that after natural menopause, averaging 1% per month during 6 months of treatment (10). This induced loss of the trabecular component of bone may be associated with adverse effects on the cancellous microstructure that are unlikely to be reversed by cessation of therapy (11 13). Add-back hormone replacement therapy (HRT), in which various agents are combined with GnRH agonist therapy, has been recommended as a means of maintaining a therapeutic response and ameliorating potential adverse effects of GnRH agonist therapy. The rationale for this approach is the estrogen threshold hypothesis (14). The hypothesis states that low levels of circulating estradiol levels are associated with regression of estrogen-sensitive tissues (e.g., endometriotic implants) and that adding back small amounts of estrogen will increase circulating levels enough to maintain the integrity of some tissues, such as bone, with relief of vasomotor symptoms, while causing other tissues (e.g., endometriotic lesions) to remain in a state of regression. We sought to investigate whether administration of addback therapy with a continuous combined estrogen-progestin preparation reduces the vasomotor symptoms and bone loss associated with GnRH agonist therapy without compromising its efficacy in the treatment of endometriosis. MATERIALS AND METHODS Design and Patients We performed a prospective, randomized, placebo-controlled, double-blind, multicenter trial. Written approval for the study was obtained from the Institutional Review Board of each participating hospital. We included 41 women with endometriosis confirmed by laparoscopy in the 3 months before initiation of treatment. At the time of laparoscopy, endometriosis was scored according to the revised American Fertility Society (AFS-R) classification (15); patients in our study had AFS-R scores of 2 or more. No attempt was made to reduce the endometriotic lesions. All patients gave written informed consent before inclusion. Treatment After the presence of endometriosis was confirmed by laparoscopy, patients were randomly assigned in blocks of 4 to 24 weeks of treatment with a subcutaneous depot formulation of goserelin acetate (Zoladex; AstraZeneca, Zoetermeer, the Netherlands), 3.6 mg, every 4 weeks plus either an oral combination of 2 mg 17 -E 2 and 1 mg norethisterone acetate (Kliogest; Novo Nordisk, Alphen aan de Rijn, The Netherlands) or oral placebo (identical in appearance to Kliogest) daily for 24 weeks. Therapy was started during menstruation. Outcome Measures Endometriosis Response All patients underwent laparoscopy in the 3 months before initiation of therapy and again between 4 and 6 weeks after the final injections of goserelin acetate. If indicated on follow-up laparoscopy, laser vaporization, electrocautery or ultracision of the endometriotic lesions or adhesions was performed. Bone Mineral Density Bone mineral density was measured by using dual-energy X-ray absorptiometry (Lunar DPXL, Old Delft, Delft, The Netherlands; or Hologic QDR-4500A, Hologic, Waltham, MA, U.S.A.) of the lumbar spine (L2 to L4) and is expressed in g/cm 2. Bone mass was measured after the initial laparoscopy but before the first goserelin depot was given and at completion of 24 weeks of therapy. Transvaginal Ultrasonography Transvaginal ultrasonography was performed just before starting treatment and at completion of 24 weeks of therapy. The endometrial thickness, calculated as the maximum distance between the echogenic interfaces of the myometrium and the endometrium, was measured in the plane through the central axis of the uterus. The mean area of both the ovaries was estimated by using the measurements of the maximum diameters of the ovaries in the transversal plane under the assumption that the ovaries were elliptical. The formula used to calculate the mean area of the ovaries is as follows: 1/4 long right trans right ) (1/4 long left trans left ) 2 in which long is the longitudinal axis and trans is the transverse axis. Endocrinologic Effects Serum FSH and E 2 concentrations were measured on day 3 of the cycle immediately before initiation of treatment and at 24 weeks, 1 day after ingestion of the last tablet. Subjective Side Effects The Kupperman index was used to characterize climacteric symptoms. The following symptoms were scored: hot flushes, sweats, sleep, nervousness, depression, vertigo, asthenia, arthralgia, headaches, palpitations, and vaginal dry- FERTILITY & STERILITY 535

3 TABLE 1 Baseline characteristics of the study groups. Variable GnRH agonist plus placebo (n 23) GnRH agonist plus HRT (n 18) a Age (yrs) Body mass index (kg/m 2 ) Systolic blood pressure (mm hg) Diastolic blood pressure (mm Hg) Heart rate (bpm) No. of smokers (%) 7 (30.4) 6 (33.3).84 Note: Values are given as mean SD or as number (percentages) of patients. Therapy with GnRH agonist consisted of goserelin acetate; HRT consisted of 17 E 2 and norethisterone acetate. a Differences between groups were determined by using the Student t-test, the 2 test, or the Mann-Whitney U test. FIGURE 1 Mean revised American Fertility Society (AFS-R) score, before treatment (white bars) and after 24 weeks of treatment (black bars), in patients receiving GnRH agonist plus placebo or GnRH agonist plus HRT with 17 -E 2 norethisterone acetate. The decrease in AFS-R differed significantly within groups (P.05) but not between the groups (P.54). ness. The total Kupperman index score is the sum of the values of the eleven symptoms. Statistical Analysis For endometriosis response, bone mineral density, transvaginal ultrasonography, endocrinologic effects, and subjective side effects, we used the Mann Whitney U test, the unpaired Student t-test, or 2 test to compare betweengroups differences at baseline and after treatment. The Wilcoxon matched-pairs signed-rank test or paired Student t-test was used to compare within-group differences. The percentage changes from baseline in bone mineral density of the lumbar spine were calculated because the various participating hospitals used different equipment (Lunar or Hologic ). To analyze Kupperman index scores, we used Friedman two-way analysis of variance to test for within-group changes and analysis of covariance for repeated measures with the pretreatment value as constant covariate for between-group differences in changes. Statistical significance was defined as P.05. RESULTS Between April 1, 1997, and July 1, 1999, 41 patients were enrolled and assigned to study groups. The GnRH agonist plus placebo group included 23 patients and the GnRH agonist plus HRT (17 -E 2 and norethisterone acetate) included 18 patients. Baseline characteristics of the two groups did not differ significantly (Table 1). Only one patient (in the GnRH agonist plus placebo group) discontinued treatment because of severe climacteric symptoms. This patient did not undergo second-look laparoscopy. Endometriosis Response The pretreatment median AFS-R score was 28.0 (range, 6 117) in the GnRH agonist plus placebo group and 29.0 (range, 8 78) in the GnRH agonist plus HRT group. The posttreatment median AFS-R score was 6.0 (range, 0 63) in the GnRH agonist plus placebo group and 9.0 (range, 4 40) in the GnRH agonist plus HRT group. The difference between groups at both time points was not statistically significant. In both groups, the median AFS-R score was significantly reduced (P.05) (Fig. 1). The decrease was 78.6% in the GnRH agonist plus placebo group and 69% in the GnRH agonist plus HRT group; the difference between the two groups was not statistically significant (P.64). Indications for laparoscopy were pelvic pain and infertility. Seventeen patients (73.9%) in the GnRH agonist plus placebo group and 8 (44.4%) in the GnRH agonist plus HRT group had pelvic pain. Infertility was the reason for laparoscopy in 6 (26.1%) patients in the GnRH agonist plus placebo group and 10 (55.6%) patients in the GnRH agonist plus HRT group. The distribution of both indications in the different groups almost reached statistical significance (P.0549). Bone Mineral Density Pretreatment median ( SD) bone mineral density of the lumbar spine was g/cm 2 in the GnRH agonist plus placebo group and g/cm 2 in the GnRH agonist plus HRT group. The difference between groups was not statistically significant. 536 Franke et al. Endometriosis and GnRH agonist therapy Vol. 74, No. 3, September 2000

4 FIGURE 2 Bone mineral density of the lumbar spine (L2 to L4) in patients receiving GnRH agonist plus placebo (black square) or GnRH agonist plus HRT with 17 -E 2 norethisterone acetate (white circles). After 24 weeks of treatment, bone mineral density decreased 5.02% in the GnRH agonist plus placebo group and increased 0.18% in the GnRH agonist plus HRT group. (difference between groups, P.001). Posttreatment median bone mineral density of the lumbar spine was g/cm 2 in the GnRH agonist plus placebo group and g/cm 2 in the GnRH agonist plus HRT group. The difference between groups was not statistically significant. After 24 weeks of treatment, the mean bone mineral density of the lumbar spine (L2 to L4) had decreased significantly (by 5.02%) in the GnRH agonist plus placebo group, whereas it increased by 0.18% the GnRH agonist plus HRT group (Figure 2). The difference between groups was statistically significant (P.001). Transvaginal Ultrasonography At the initiation of treatment and after 24 weeks of therapy the double-layered endometrial thickness was measured and the mean area of both ovaries was calculated (Table 2). After 24 weeks of therapy, both groups experienced a statistically significant reduction in median endometrial thickness. Endometrial thickness was reduced by 43.1% P.002 in the GnRH agonist plus placebo group and 49.2% (P.009) in the GnRH agonist plus HRT group. The difference between groups was not statistically significant (P.77). The observed decrease in the median area of the ovaries was similar in both groups. After 24 weeks of treatment, the median area decreased by 31.6% in the GnRH agonist plus placebo group and 46.7% in the GnRH agonist plus HRT group. This difference was not statistically significant (P.63). Endocrinologic Effects After 24 weeks of treatment, the median serum FSH level decreased by 55.9% (P.01) in the GnRH agonist plus HRT group but by only 16.7% in the GnRH agonist plus placebo group (P.62) (Table 3). The difference in decreases between the groups was significant (P.05). The median serum E 2 level increased in both the GnRH agonist plus placebo group (P.83) and the GnRH agonist plus HRT group (P.55). However, the increase of 6.8% in TABLE 2 Transvaginal ultrasonographic findings before treatment and after 24 weeks of treatment. Group Double-layer endometrial thickness (mm) Mean area right and left ovary (mm 2 ) a Pretreatment Posttreatment Pretreatment Posttreatment endometrial thickness b endometrial thickness c area of ovary b area of ovary c GnRH agonist placebo 5.1 ( ) 2.9 ( ) 544 (155 1,266) 372 ( ) (n 23) (n 18) (n 16) (n 17) GnRH agonist HRT 6.5 ( ) 3.3 ( ) 603 (305 3,117) 321 (192 1,319) (n 17) (n 16) (n 16) (n 16) d Note: Values are given as median (range). The GnRH agonist was goserelin acetate; HRT consisted of 17 E 2 plus norethisterone acetate. a See text for formula used to calculate mean area. b Wilcoxon matched-pairs signed-rank test. c Mann-Whitney U test or Student t-test. d Mann-Whitney U test for between groups differences. FERTILITY & STERILITY 537

5 TABLE 3 Serum concentrations of FSH and E 2 before treatment and after 24 weeks of treatment. Group Pretreatment Posttreatment FSH (IU/L) E 2 (pmol/l) FSH (IU/L) E 2 (pmol/l) FSH a FSH b E 2 a E 2 c GnRH agonist placebo 6.0 (0.4 15) 117 (40 550) 5.0 (2.1 25) 125 (41 1,129) (n 23) (n 22) (n 19) (n 18).052 b.72 GnRH agonist HRT 5.9 (0.4 23) 116 (30 1,300) 2.6 (0.6 9) 280 (70 608) (n 18) (n 18) (n 18) (n 18) d Note: Values are given as median (range). The GnRH agonist was goserelin acetate; HRT consisted of 17 E 2 plus norethisterone acetate. a Wilcoxon matched-pairs signed-rank test. b Student t-test. c Mann-Whitney U test. d Mann-Whitney U test for between-groups. the GnRH agonist plus placebo was not statistically significantly different compared with the increase of 141.1% in the GnRH agonist plus HRT group (P.72). Subjective Side Effects The total Kupperman index score was calculated just before treatment was begun and at 4, 12, and 24 weeks after initiation of therapy (Fig. 3). The reduction in Kupperman index score in the GnRH agonist plus placebo group was FIGURE 3 Total Kupperman index score before treatment and at 4, 12, and 24 weeks after initiation of therapy in patients receiving GnRH agonist plus placebo (black squares) or GnRH agonist plus HRT with 17 -E 2 norethisterone acetate (white circles). In the GnRH agonist plus placebo group, the Kupperman index score decreased by 75% at 4 weeks, 129% at 12 weeks, and 113% at 24 weeks (P.0004). The difference between groups at 24 weeks was statistically significant (P.003). 75%, at 4 weeks, 129% at 12 weeks, and 113% at 24 weeks (P.004). The difference between the GnRH agonist plus placebo group and the GnRH agonist plus HRT group at 24 weeks was statistically significant (P.003). DISCUSSION Few prospective randomized trials of follow-up laparoscopy in patients with endometriosis treated with GnRH agonist plus placebo or GnRH agonist plus HRT have been published (5 9). The results of these investigations made it clear that the addition of different HRT regimens to GnRH agonist treatment for endometriosis did not influence the healing of the endometriotic implants but ameliorated subjective side effects of therapy and did not reduce bone mineral density. In the placebo group of two studies (5, 6), bone mineral densities decreased; one of these study noted reversibility (5). The type of add-back HRT is not particularly important; rather, what is important is that some type of add-back therapy is given. Compston et al. (12) demonstrated a deleterious effect to the bone microstructure induced by GnRH agonists without add-back therapy. Adverse effects on the cancellous microstructure will follow, which are unlikely to be reversed after cessation of therapy and may lead to increased risk for fracture in later life. Paoletti et al. (13) observed a complete reversal of lumbar bone mineral density loss 2 years after completion of 6 months of GnRH agonist therapy without add-back in patients with endometriosis. However, bone mineral density does not measure the microstructure of cancellous bone; increased risk for fracture may therefore be present despite demonstrable restoration of bone mineral density. Bone mineral density measurements are relevant because 538 Franke et al. Endometriosis and GnRH agonist therapy Vol. 74, No. 3, September 2000

6 relatively small decreases can produce an increase in actual risk for fracture. Because of their antiresorptive capacity, estrogens are widely accepted as having a central role in protecting the female skeleton. Estrogenic action is not uniform throughout the skeleton; the vertebrae of the lumbar spine are especially susceptible to hypoestrogenism because they are composed of more than 70% trabecular bone, whereas the appendicular skeleton of the limbs are less sensitive. Most patients achieve relief of subjective side effects within 1 month of commencing therapy. This relief may continue for 6 months after cessation of treatment, but some women, usually those with higher disease scores before treatment, experience rapid recurrence of symptoms. These women may benefit from prolonged GnRH agonist administration, preferably with add-back therapy. The demonstration of recurrent endometriotic lesions after 24 weeks of GnRH agonist treatment with or without add-back therapy emphasizes the fact that extension of treatment would benefit patients with endometriosis. Because addition of HRT to GnRH agonist treatment in these patients will neither influence the microstructure of cancellous bone nor interfere with healing of endometriotic implants (according to laparoscopy) and will decrease subjective side effects, we recommend a standard combination of GnRH agonist treatment with a continuous combined estrogen-progestin preparation. Long-term studies are needed to determine whether treatment for more than 24 weeks without unwanted side effects is possible. Acknowledgments: The authors thank Mrs. E.R.A. Peters-Muller, M.Sc., for data management and statistical analysis; the Dutch HRT-Network Foundation for logistical management of the trial; and the research nurses of the participating hospitals. They also thank H. Sipko Mülder, M.Sc., Ph.D., of AstraZeneca for his continuous support during the trial. Participating investigators in the trial were Henk R. Franke, M.D., Ph.D. (Enschede); Robert- Jan Iding, M.D. (Venray); Hans C.L.V. Kock, M.D., Ph.D. (Tilburg); Ton M.M. Pennings, M.D. (Den Helder); Jacqueliene J.P.M. Pieters, M.D. (Tilburg); and Peter H.M. van de Weijer, M.D., Ph.D. (Apeldoorn). References 1. Sampson JA. Perforating hemorrhagic (chocolate) cysts of the ovary. Arch Surg 1921;3: Dmowski WP, Steele RW, Baker GF. Deficient cellular immunity in endometriosis. Am J Obstet Gynecol 1981;141: Surrey ES. Add-back therapy and gonadotropin-releasing hormone agonists in the treatment of patients with endometriosis: can a consensus be reached? The Add-back Consensus Working Group. Fertil Steril 1999;71: Hornstein MD, Surrey ES, Weisberg GW, Casino LA. Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group. Obstet Gynecol 1998;91: Surrey ES, Judd H. Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial. J Clin Endocrinol Metab 1992;75: Howell R, Edmonds DK, Dowsett M, Crook D, Lees B, Stevenson JS. Gonadotropin-releasing hormone analogue (goserelin) plus hormone replacement therapy for the treatment of endometriosis: a randomized controlled trial. Fertil Steril 1995;3: Kiiholma P, Korhonen M, Tuimala R, Korhonen M, Hagman E. Comparison of the gonadotropin-releasing hormone agonist goserelin acetate alone versus goserelin combined with estrogen-progestagen addback therapy in the treatment of endometriosis. Fertil Steril 1995;64: Makarainen L, Ronneberg L, Kauppila A. Medroxyprogesterone acetate supplementation diminishes the hypoestrogenic side-effects of gonadotropin-releasing hormone agonists without changing its efficacy in endometriosis. Fertil Steril 1996;65: Taskin O, Yalcinoglu AI, Kucuk S, Uryan I, Buhur A, Burak F. Effectiveness of tibolone on hypoestrogenic symptoms induced by goserelin treatment in patients with endometriosis. Fertil Steril 1997; 67: Pickersgill A. GnRH agonists and add-back therapy: is there a perfect combination? Br J Obstet Gynaecol 1998;105: Leather AT, Studd JWW, Watson NR, Holland EFN. The prevention of bone loss in young women treated with GnRH analogues with addback estrogen therapy. Obstet Gynecol 1993;83: Compston JE, Yamaguchi K, Croucher PI, Garrahan NJ, Lindsay PC, Shaw RW. The effects of gonadotropin-releasing hormone agonists on iliac crest cancellous bone structure in women with endometriosis. Bone 1995;16: Paoletti AM, Serra GG, Cagnacci A, Vacca AMB, Guerriero S, Solla S, et al. Spontaneous reversibility of bone loss induced by gonadotropinreleasing hormone analog treatment. Fertil Steril 1996;65: Barbieri R. Hormone treatment of endometriosis: the estrogen threshold hypothesis. Am J Obstet Gynecol 1992;166: American Society for Reproductive Medicine. Revised American Society for Reproductive Medicine classification of endometriosis: Fertil Steril 1997;67: FERTILITY & STERILITY 539

Key Words: Endometriosis, GnRH-a, goserelin, Zoladex, estrogen, sex-steroid add-back therapy,

Key Words: Endometriosis, GnRH-a, goserelin, Zoladex, estrogen, sex-steroid add-back therapy, FERTLTY AND STERLTY Copyright 1995 American Society for Reproductive Medicine Vol. 64, No. 5, November 1995 Printed on acid free paper in U. S. A. Comparison of the gonadotropin-releasing hormone agonist

More information

Int J Clin Exp Med 2013;6(7): /ISSN: /IJCEM Yi Han 1,2, Shi-En Zou 1, Qi-Qi Long 1, Shao-Fen Zhang 1

Int J Clin Exp Med 2013;6(7): /ISSN: /IJCEM Yi Han 1,2, Shi-En Zou 1, Qi-Qi Long 1, Shao-Fen Zhang 1 Int J Clin Exp Med 2013;6(7):583-588 www.ijcem.com /ISSN:1940-5901/IJCEM1306010 Original Article The incidence and characteristics of uterine bleeding during postoperative GnRH agonist treatment combined

More information

A Prospective Observational Study to Evaluate the Efficacy and Safety Profiles of Leuprorelin 3 Month Depot for the Treatment of Pelvic Endometriosis

A Prospective Observational Study to Evaluate the Efficacy and Safety Profiles of Leuprorelin 3 Month Depot for the Treatment of Pelvic Endometriosis SH SUEN & SCS CHAN A Prospective Observational Study to Evaluate the Efficacy and Safety Profiles of Leuprorelin 3 Month Depot for the Treatment of Pelvic Endometriosis Sik Hung SUEN MBChB, MRCOG Resident

More information

Effects of different add-back regimens on hypoestrogenic problems by postoperative gonadotropin-releasing hormone agonist treatment in endometriosis

Effects of different add-back regimens on hypoestrogenic problems by postoperative gonadotropin-releasing hormone agonist treatment in endometriosis Original Article Obstet Gynecol Sci 2016;59(1):32-38 http://dx.doi.org/10.5468/ogs.2016.59.1.32 pissn 2287-8572 eissn 2287-8580 Effects of different add-back regimens on hypoestrogenic problems by postoperative

More information

Gynecology-endocrinology

Gynecology-endocrinology Gynecology-endocrinology FERTILITY AND STERILITY Vol. 64, No.3, September 1995 Copyright C> 1995 American Society for Reproductive Medicine Printed on acid-free paper in U. S. A. Gonadotropin-releasing

More information

CY Tse, AMK Chow, SCS Chan. Introduction

CY Tse, AMK Chow, SCS Chan. Introduction Effects of an extended-interval dosing regimen of triptorelin depot on the hormonal profile of patients with endometriosis: prospective observational study CY Tse, AMK Chow, SCS Chan Objective. To evaluate

More information

MANAGEMENT OF REFRACTORY ENDOMETRIOSIS

MANAGEMENT OF REFRACTORY ENDOMETRIOSIS (339) MANAGEMENT OF REFRACTORY ENDOMETRIOSIS Serdar Bulun, MD JJ Sciarra Professor and Chair Department of Ob/Gyn Northwestern University ENDOMETRIOSIS OCs Teenager: severe dysmenorrhea often starting

More information

Int J Clin Exp Med 2016;9(10): /ISSN: /IJCEM

Int J Clin Exp Med 2016;9(10): /ISSN: /IJCEM Int J Clin Exp Med 2016;9(10):19935-19943 www.ijcem.com /ISSN:1940-5901/IJCEM0027833 Original Article Clinical outcome of various regimens of gonadotropin-releasing hormone analogues after conservative

More information

ORILISSA (elagolix) oral tablet

ORILISSA (elagolix) oral tablet ORILISSA (elagolix) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage

More information

CASE 4- Toy et al. CASE FILES: Obstetrics & Gynecology

CASE 4- Toy et al. CASE FILES: Obstetrics & Gynecology CASE 4- Toy et al. CASE FILES: Obstetrics & Gynecology A 49-year-old woman complains of irregular menses over the past 6 months, feelings of inadequacy, vaginal dryness, difficulty sleeping, and episodes

More information

Endometriosis Treatment & Management Medscape

Endometriosis Treatment & Management Medscape Endometriosis Treatment & Management Medscape Updated: Apr 25, 2016 Author: G Willy Davila, MD; Chief Editor: Michel E Rivlin, MD more... Approach Considerations The dependence of endometriosis on the

More information

Page 1 of 8 Official reprint from UpToDate www.uptodate.com 2012 UpToDate The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.

More information

Results of implication of aromatase inhibitors in therapy of genital endometriosis Yarmolinskaya M. (Speaker), Bezhenar V., Molotkov A.

Results of implication of aromatase inhibitors in therapy of genital endometriosis Yarmolinskaya M. (Speaker), Bezhenar V., Molotkov A. Results of implication of aromatase inhibitors in therapy of genital endometriosis Yarmolinskaya M. (Speaker), Bezhenar V., Molotkov A. Ott's Research Institute of Obstetrics, Gynecology and Reproductology,

More information

Department of Obstetrics and Gynecology, Chosun University School of Medicine, Gwangju, Korea

Department of Obstetrics and Gynecology, Chosun University School of Medicine, Gwangju, Korea J MM pissn: 2288-6478, eissn: 2288-6761 Journal of Menopausal Medicine 2016;22:174-179 Original Article Raloxifene Administration in Women Treated with Long Term Gonadotropin-releasing Hormone Agonist

More information

Palm Beach Obstetrics & Gynecology, PA

Palm Beach Obstetrics & Gynecology, PA Palm Beach Obstetrics & Gynecology, PA 4671 S. Congress Avenue, Lake Worth, FL 33461 561.434.0111 4631 N. Congress Avenue, Suite 102, West Palm Beach, FL 33407 Endometriosis The lining of the uterus is

More information

PERIMENOPAUSE. Objectives. Disclosure. The Perimenopause Perimenopause Menopause. Definitions of Menopausal Transition: STRAW.

PERIMENOPAUSE. Objectives. Disclosure. The Perimenopause Perimenopause Menopause. Definitions of Menopausal Transition: STRAW. PERIMENOPAUSE Patricia J. Sulak, MD Founder, Living WELL Aware LLC Author, Should I Fire My Doctor? Author, Living WELL Aware: Eleven Essential Elements to Health and Happiness Endowed Professor Texas

More information

GnRH agonist and antagonist: Options for endometriosis pain treatment

GnRH agonist and antagonist: Options for endometriosis pain treatment Thomas Jefferson University Jefferson Digital Commons Department of Obstetrics and Gynecology Faculty Papers Department of Obstetrics and Gynecology November 2006 GnRH agonist and antagonist: Options for

More information

Treatment of hirsutism with a gonadotropin-releasing hormone agonist and estrogen replacement therapy*

Treatment of hirsutism with a gonadotropin-releasing hormone agonist and estrogen replacement therapy* Gynecology-endocrinology FERTILITY AND STERILITY Copyright 1994 The American Fertility Society Printed on acid-free paper in U S. A. Treatment of hirsutism with a gonadotropin-releasing hormone agonist

More information

Orilissa (elagolix) NEW PRODUCT SLIDESHOW

Orilissa (elagolix) NEW PRODUCT SLIDESHOW Orilissa (elagolix) NEW PRODUCT SLIDESHOW Introduction Brand name: Orilissa Generic name: Elagolix Pharmacological class: GnRH antagonist Strength and Formulation: 150mg, 200mg; tabs Manufacturer: AbbVie

More information

Endometriosis. What you need to know. 139 Dumaresq Street Campbelltown Phone Fax

Endometriosis. What you need to know. 139 Dumaresq Street Campbelltown Phone Fax Endometriosis What you need to know 139 Dumaresq Street Campbelltown Phone 4628 5292 Fax 4628 0349 www.nureva.com.au September 2015 What is Endometriosis? Endometriosis is a condition whereby the lining

More information

The Use of GnRH Agonists in the Treatment of Endometriomas With or Without Drainage

The Use of GnRH Agonists in the Treatment of Endometriomas With or Without Drainage The Use of GnRH Agonists in the Treatment of Endometriomas With or Without Drainage Pages with reference to book, From 30 To 32 Sertac Batioglu, Havva Celikkanat, Mustafa Ugur, Leyla Mollamahmutoglu, Huseyin

More information

Endometriosis. *Chocolate cyst in the ovary

Endometriosis. *Chocolate cyst in the ovary Endometriosis What is endometriosis? Endometriosis is a common condition in young women. It's chronic, painful, and it often progressively gets worse over the time. *Chocolate cyst in the ovary Normally,

More information

t Funded by a grant from TAP Pharmaceuticals, Deerfield, Illinois.

t Funded by a grant from TAP Pharmaceuticals, Deerfield, Illinois. FERTILITY AND STERILITY Vol. 63, No.4, April 1995 Copyright 1995 American Society for Reproductive Medicine Printed on acid-free paper in U. S. A. Prolonged gonadotropin-releasing hormone agonist treatment

More information

me LUTEINIZED UNRUPTURED FOLLICLE SYNDROME AND ENDOMETRIOSIS

me LUTEINIZED UNRUPTURED FOLLICLE SYNDROME AND ENDOMETRIOSIS FERTILITY AND STERILITY Copyright c 980 The American Fertility Society Vol. 33,, JanuaEY 980 Printed in U.S.A. me LUTEINIZED UNRUPTURED FOLLICLE SYNDROME AND ENDOMETRIOSIS W. PAULDMOWSKI, M.D.,.PH.D.*

More information

Reproductive Health and Pituitary Disease

Reproductive Health and Pituitary Disease Reproductive Health and Pituitary Disease Janet F. McLaren, MD Assistant Professor Division of Reproductive Endocrinology and Infertility Department of Obstetrics and Gynecology jmclaren@uabmc.edu Objectives

More information

- Linzagolix overall efficacy and safety maintained or improved at week 24

- Linzagolix overall efficacy and safety maintained or improved at week 24 Final results of ObsEva SA Phase 2b EDELWEISS trial of Linzagolix show sustained efficacy and Bone Mineral Density safety, for the treatment of endometriosis-associated pain - Linzagolix overall efficacy

More information

Western Locality Shared care information ~ Gonadorelin Analogues (Gnrh)

Western Locality Shared care information ~ Gonadorelin Analogues (Gnrh) Western Locality Shared care information ~ Gonadorelin Analogues (Gnrh) Specialist: Please complete the Shared Care letter sending a request to GP (see bottom of the page) April 2013 GP: Please indicate

More information

Post-menopausal hormone replacement therapy. Evan Klass, MD May 17, 2018

Post-menopausal hormone replacement therapy. Evan Klass, MD May 17, 2018 Post-menopausal hormone replacement therapy Evan Klass, MD May 17, 2018 Are we really still talking about this? Are we really still talking about this? 1960-1975- estrogen prescriptions doubled. Pharma

More information

Hormonal Control of Human Reproduction

Hormonal Control of Human Reproduction Hormonal Control of Human Reproduction Bởi: OpenStaxCollege The human male and female reproductive cycles are controlled by the interaction of hormones from the hypothalamus and anterior pituitary with

More information

Hormones friend or foe? Undertreatment and quality of life. No conflicts of interest to declare

Hormones friend or foe? Undertreatment and quality of life. No conflicts of interest to declare Hormones friend or foe? Undertreatment and quality of life Anette Tønnes Pedersen MD, Ph.D. Consultant, Associate professor Dept. Of Gynecology / Fertility Clinic Rigshospitalet No conflicts of interest

More information

25 mg oestradiol implants--the dosage of first choice for subcutaneous oestrogen replacement therapy?

25 mg oestradiol implants--the dosage of first choice for subcutaneous oestrogen replacement therapy? Research Subcutaneous estrogen replacement therapy. Jones SC. Journal of Reproductive Medicine March, 2004; 49(3):139-142. Department of Obstetrics and Gynecology, Keesler Medical Center, Keesler Air Force

More information

Original Policy Date

Original Policy Date MP 5.01.30 Implantable Hormone Pellets Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Local Policy created with literature search/12:2013 Return

More information

Smita Jain, M.B., M.S.* and Maureen E. Dalton, F.R.C.O.G. Sunderland Royal Hospital, Sunderland, Tyne and Wear, United Kingdom

Smita Jain, M.B., M.S.* and Maureen E. Dalton, F.R.C.O.G. Sunderland Royal Hospital, Sunderland, Tyne and Wear, United Kingdom ENDOMETRIOSIS FERTILITY AND STERILITY VOL. 72, NO. 5, NOVEMBER 1999 Copyright 1999 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Chocolate

More information

Medical treatment for uterine fibroids

Medical treatment for uterine fibroids Medical treatment for uterine fibroids Prof Mary Ann Lumsden Prof of Gynaecology and Medical Education University of Glasgow Senior Vice President RCOG Conflict of Interest Chair, Guideline development

More information

Drug Class Monograph

Drug Class Monograph Drug Class Monograph Class: Gonadotropin Releasing Hormone (GnRH) Analogs Drugs: Eligard (leuprolide acetate), Firmagon (degarelix), Lupaneta Pack (leuprolide acetate and norethindrone), Lupron Depot (leuprolide

More information

Endometriosis. Assoc.Prof.Pawin Puapornpong, Faculty of Medicine, Srinakharinwirot University.

Endometriosis. Assoc.Prof.Pawin Puapornpong, Faculty of Medicine, Srinakharinwirot University. Endometriosis Assoc.Prof.Pawin Puapornpong, Faculty of Medicine, Srinakharinwirot University. Endometriosis Definition: Ectopic Endometrial Tissue True Incidence Unknown:? 1-5% Does NOT Discriminate by

More information

2.0 Synopsis. Lupron Depot M Clinical Study Report R&D/09/093. (For National Authority Use Only) to Part of Dossier: Name of Study Drug:

2.0 Synopsis. Lupron Depot M Clinical Study Report R&D/09/093. (For National Authority Use Only) to Part of Dossier: Name of Study Drug: 2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: Name of Study Drug: Volume: Abbott-43818 (ABT-818) leuprolide acetate for depot suspension (Lupron Depot ) Name of

More information

Gonadotropin Releasing Hormone (GnRH) Analogs Drug Class Prior Authorization Protocol

Gonadotropin Releasing Hormone (GnRH) Analogs Drug Class Prior Authorization Protocol Gonadotropin Releasing Hormone (GnRH) Analogs Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been

More information

Effect of combined therapy GnRH-a plus add-back tibolone on endocrine hormone levels and bone loss in endometriosis patients.

Effect of combined therapy GnRH-a plus add-back tibolone on endocrine hormone levels and bone loss in endometriosis patients. Biomedical Research 2017; 28 (11): 4787-4791 ISSN 0970-938X www.biomedres.info Effect of combined therapy GnRH-a plus add-back tibolone on endocrine hormone levels and bone loss in endometriosis patients.

More information

CASE 41. What is the pathophysiologic cause of her amenorrhea? Which cells in the ovary secrete estrogen?

CASE 41. What is the pathophysiologic cause of her amenorrhea? Which cells in the ovary secrete estrogen? CASE 41 A 19-year-old woman presents to her gynecologist with complaints of not having had a period for 6 months. She reports having normal periods since menarche at age 12. She denies sexual activity,

More information

CNGOF Guidelines for the Management of Endometriosis

CNGOF Guidelines for the Management of Endometriosis CNGOF Guidelines for the Management of Endometriosis Anatomoclinical forms of endometriosis Definitions Endometriosis is defined as the presence of endometrial tissue containing both glands and stroma

More information

(For National Authority Use Only) Name of Study Drug: to Part of Dossier:

(For National Authority Use Only) Name of Study Drug: to Part of Dossier: 2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Abbott-43818 (ABT-818) leuprolide acetate for depot suspension

More information

Definition Endometriosis is the presence of functioning endometrial tissue outside the cavity of the uterus.

Definition Endometriosis is the presence of functioning endometrial tissue outside the cavity of the uterus. Dept. of Obstetrics t and Gynecology Faculty of Medicine University of Sumatera Utara Endometriosis Definition Endometriosis is the presence of functioning endometrial tissue outside the cavity of the

More information

Pre and post surgical medical therapy. Mauro Busacca M.D. Dept of Obstetrics and Gynecology University of Milan- Italy

Pre and post surgical medical therapy. Mauro Busacca M.D. Dept of Obstetrics and Gynecology University of Milan- Italy Pre and post surgical medical therapy Mauro Busacca M.D. Dept of Obstetrics and Gynecology University of Milan- Italy introduction A disease is an open problem when two conditions are nor satisfied: The

More information

Medical Management of Endometriosis: Novel Targets and Future Treatments Erkut Attar, M.D. PhD.

Medical Management of Endometriosis: Novel Targets and Future Treatments Erkut Attar, M.D. PhD. Medical Management of Endometriosis: Novel Targets and Future Treatments Erkut Attar, M.D. PhD. Istanbul University Istanbul Medical School Department of Obstetrics & Gynecology Division of Reproductive

More information

Use of Ovarian Suppression and Ablation in Breast Cancer Treatment

Use of Ovarian Suppression and Ablation in Breast Cancer Treatment Use of Ovarian Suppression and Ablation in Breast Cancer Treatment Dr Marina Parton Consultant Medical Oncologist Royal Marsden and Kingston Hospitals Overview Breast cancer phenotypes Use of ovarian manipulation

More information

The pharmacological management of ENDOMETRIOSIS

The pharmacological management of ENDOMETRIOSIS The pharmacological management of ENDOMETRIOSIS 18 Endometriosis is a gynaecological condition in which endometrial tissue is present outside the uterine cavity, causing cyclic symptoms and, often, reduced

More information

Learning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories

Learning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories Learning Objectives Identify common symptoms of the menopause transition Understand the risks and benefits of hormone replacement therapy (HRT) Be able to choose an appropriate hormone replacement regimen

More information

EVALUATION OF WOMEN FOLLOWING HYSTERECTOMY WITH AND WITHOUT CONSERVATION OF OVARIES

EVALUATION OF WOMEN FOLLOWING HYSTERECTOMY WITH AND WITHOUT CONSERVATION OF OVARIES Int. J. Chem. Sci.: 6(3), 2008, 1228-1235 EVALUATION OF WOMEN FOLLOWING HYSTERECTOMY WITH AND WITHOUT CONSERVATION OF OVARIES RAMPRASAD DEY, SUBHASH CHANDRA BISWAS, RANU ROY BISWAS a and ARUNIMA MUKHOPADHYAY

More information

Dienogest compared with gonadotropin-releasing hormone agonist after conservative surgery for endometriosis

Dienogest compared with gonadotropin-releasing hormone agonist after conservative surgery for endometriosis doi:10.1111/jog.13023 J. Obstet. Gynaecol. Res. Vol. 42, No. 9: 1152 1158, September 2016 Dienogest compared with gonadotropin-releasing hormone agonist after conservative surgery for endometriosis Yotaro

More information

Endometriosis. A Guide for Patients PATIENT INFORMATION SERIES

Endometriosis. A Guide for Patients PATIENT INFORMATION SERIES Endometriosis A Guide for Patients PATIENT INFORMATION SERIES Published by the American Society for Reproductive Medicine under the direction of the Patient Education Committee and the Publications Committee.

More information

Management of Perimenopausal symptoms

Management of Perimenopausal symptoms Management of Perimenopausal symptoms Serge Rozenberg CHU St Pierre Université libre de Bruxelles Belgium serge_rozenberg@stpierre-bru.be serge.rozenberg@skynet.be Conflict of interest & Disclosure Conflicts

More information

Menopause and HRT. John Smiddy and Alistair Ledsam

Menopause and HRT. John Smiddy and Alistair Ledsam Menopause and HRT John Smiddy and Alistair Ledsam Menopause The cessation of menstruation Diagnosed retrospectively after 1 year of amenorrhoea Average age 51 in the UK Normal physiology - Menstruation

More information

The facts about Endometriosis

The facts about Endometriosis The facts about Endometriosis A specialist team of health professionals with the expertise to provide personalised and up to date treatment for women with endometriosis. Nurse Co ordinator Gynaecologists

More information

Department of Obstetrics and Gynaecology, Royal Surrey County Hospital, Guildford, United Kingdom

Department of Obstetrics and Gynaecology, Royal Surrey County Hospital, Guildford, United Kingdom FERTILITY AND STERILITY Vol. 62, No.4, October 1994 Copyright c 1994 The American Fertility Society Printed on acid-free paper in U. S. A. Prospective, randomized, double-blind, controlled trial of laser

More information

Laparoscopy and Endometriosis: Preventing Complications and Improving Outcomes. Luis C. Paez M.D.

Laparoscopy and Endometriosis: Preventing Complications and Improving Outcomes. Luis C. Paez M.D. Laparoscopy and Endometriosis: Preventing Complications and Improving Outcomes Luis C. Paez M.D. Assumptions Pelvic pain Not desiring immediate fertility H & P suggest endometriosis OC/NSAID failures Endo

More information

Difference Between PCOS and Endometriosis

Difference Between PCOS and Endometriosis Difference Between PCOS and Endometriosis www.differencebetween.com Key Difference PCOS vs Endometriosis Ovaries play an important role in the reproduction and the maintenance of the female body. They

More information

Clinical Policy: Goserelin Acetate (Zoladex) Reference Number: ERX.SPA.145 Effective Date:

Clinical Policy: Goserelin Acetate (Zoladex) Reference Number: ERX.SPA.145 Effective Date: Clinical Policy: (Zoladex) Reference Number: ERX.SPA.145 Effective Date: 10.01.16 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

Buserelin acetate in the treatment of pelvic pain associated with minimal and mild endometriosis: a controlled study*

Buserelin acetate in the treatment of pelvic pain associated with minimal and mild endometriosis: a controlled study* .. FERTILITY AND STERILITY Copyright 99 The American Fertility Society Vol. 59, No., March 99 Printed on acid-free paper in U.S.A. Buserelin acetate in the treatment of pelvic pain associated with minimal

More information

GONADOTROPIN RELEASING HORMONE ANALOGS

GONADOTROPIN RELEASING HORMONE ANALOGS UnitedHealthcare Commercial Medical Benefit Drug Policy GONADOTROPIN RELEASING HORMONE ANALOGS Policy Number: PHA025 Effective Date: March 1, 2019 Table of Contents Page COVERAGE RATIONALE... 1 U.S. FOOD

More information

Bazedoxifene/conjugated estrogens in combination with leuprolide for the treatment of endometriosis

Bazedoxifene/conjugated estrogens in combination with leuprolide for the treatment of endometriosis CASE REPORT Bazedoxifene/conjugated estrogens in combination with leuprolide for the treatment of endometriosis Amanda M. Hill 1, Bruce Lessey 2, Valerie A. Flores 1 & Hugh S. Taylor 1 1 Yale School of

More information

ENDOMETRIOSIS: ROLE OF OVARIAN STEROIDS IN INITIATION, MAINTENANCE, AND SUPPRESSION

ENDOMETRIOSIS: ROLE OF OVARIAN STEROIDS IN INITIATION, MAINTENANCE, AND SUPPRESSION FERTILITY AND STERILITY Copyright e 1980 The American Fertility Society Vol. 33, No.6, June 1980 Printed in U.SA. ENDOMETRIOSIS: ROLE OF OVARIAN STEROIDS IN INITIATION, MAINTENANCE, AND SUPPRESSION GERE

More information

Timur Giirgan, M.D.* Bulent Urman, M.D. Hakan Yarali, M.D. Hakan E. Duran, M.D.

Timur Giirgan, M.D.* Bulent Urman, M.D. Hakan Yarali, M.D. Hakan E. Duran, M.D. FERTILITY AND STEFULI~ Vol. 68, No. 3, September 1997 Copyright 1997 American Society for Reproductive Medicine Printed on acid-free paper in U. S. A. Published by Elsevier Science Inc. Follicle-stimulating

More information

TheFormationofaScoringSystemtoDiagnoseEndometriosis. The Formation of a Scoring System to Diagnose Endometriosis

TheFormationofaScoringSystemtoDiagnoseEndometriosis. The Formation of a Scoring System to Diagnose Endometriosis Global Journal of Medical Research: E Gynecology and Obstetrics Volume 18 Issue 1 Version 1.0 Type: Double Blind Peer Reviewed International Research Journal Publisher: Global Journals Online ISSN: 49-4618

More information

Management of Menopausal Symptoms

Management of Menopausal Symptoms Management of Menopausal Symptoms Tammie Koehler DO, FACOG 1 Menopause Permanent cessation of menstruation that occurs after the loss of ovarian activity Determined to have occurred after 1 full year of

More information

Immediate and delayed add-back hormonal replacement therapy during ultra long GnRH agonist treatment of chronic cyclical pelvic pain

Immediate and delayed add-back hormonal replacement therapy during ultra long GnRH agonist treatment of chronic cyclical pelvic pain DOI: 10.1111/j.1471-0528.2009.02319.x www.bjog.org General gynaecology Immediate and delayed add-back hormonal replacement therapy during ultra long GnRH agonist treatment of chronic cyclical pelvic pain

More information

M0BCore Safety Profile. Active substance: Triptorelin Pharmaceutical form(s)/strength: 0,1 mg P-RMS: DE/H/PSUR/0038/002 Date of FAR:

M0BCore Safety Profile. Active substance: Triptorelin Pharmaceutical form(s)/strength: 0,1 mg P-RMS: DE/H/PSUR/0038/002 Date of FAR: M0BCore Safety Profile Active substance: Triptorelin Pharmaceutical form(s)/strength: 0,1 mg P-RMS: DE/H/PSUR/0038/002 Date of FAR: 26.05.2014 4.3 Contraindications Hypersensitivity to GnRH, its analogues

More information

Hormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals

Hormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals Hormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals Literature Review (January 2009) Hormone Therapy for Women Women's Health

More information

SPRMs in Gynecology. Claude-A. Fortin md Asst.Prof Ob-Gyn McGill University Montreal

SPRMs in Gynecology. Claude-A. Fortin md Asst.Prof Ob-Gyn McGill University Montreal SPRMs in Gynecology Claude-A. Fortin md Asst.Prof Ob-Gyn McGill University Montreal Disclosure Consultant : Johnson & Johnson Speaker : Pfizer, Warner Chilcott, Ethicon (Gynecare ), Actavis Research Grants

More information

Endometriosis Samuel J. Chantilis, M.D.

Endometriosis Samuel J. Chantilis, M.D. Endometriosis Samuel J. Chantilis, M.D. I. INTRODUCTION Endometriosis is the presence and growth of glands and stroma identical to the lining of the uterus in an aberrant location. Common symptoms of endometriosis

More information

Cigna Drug and Biologic Coverage Policy

Cigna Drug and Biologic Coverage Policy Cigna Drug and Biologic Coverage Policy Subject Infertility Injectables Table of Contents Coverage Policy... 1 General Background...16 Coding/Billing Information...20 References...20 Effective Date...

More information

Clinical Policy: Goserelin Acetate (Zoladex) Reference Number: CP.PHAR.171 Effective Date: 02/16

Clinical Policy: Goserelin Acetate (Zoladex) Reference Number: CP.PHAR.171 Effective Date: 02/16 Clinical Policy: (Zoladex) Reference Number: CP.PHAR.171 Effective Date: 02/16 Last Review Date: 02/17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal information.

More information

Thyroid Dysfunction Associated with Administration of the Long-Acting Gonadotropin-Releasing Hormone Agonist

Thyroid Dysfunction Associated with Administration of the Long-Acting Gonadotropin-Releasing Hormone Agonist Case Report Endocrinol Metab 2013;28:221-225 http://dx.doi.org/10.3803/enm.2013.28.3.221 pissn 2093-596X eissn 2093-5978 Thyroid Dysfunction Associated with Administration of the Long-Acting Gonadotropin-Releasing

More information

MENOPAUSE. I have no disclosures 10/11/18 OBJECTIVES WHAT S NEW? WHAT S SAFE?

MENOPAUSE. I have no disclosures 10/11/18 OBJECTIVES WHAT S NEW? WHAT S SAFE? MENOPAUSE WHAT S NEW? WHAT S SAFE? I have no disclosures Sara Whetstone, MD, MHS OBJECTIVES To describe risks of HT by age and menopause onset To recommend specific HT regimen for women who undergo early

More information

This leaflet format has been determined by the Ministry of Health and the content thereof has been checked and approved June 2013.

This leaflet format has been determined by the Ministry of Health and the content thereof has been checked and approved June 2013. This leaflet format has been determined by the Ministry of Health and the content thereof has been checked and approved June 2013. 1. NAME OF THE MEDICINAL PRODUCT ZOLADEX TM 2. QUALITATIVE AND QUANTITATIVE

More information

Menopause & HRT. Matt McKenna Elliot Davis

Menopause & HRT. Matt McKenna Elliot Davis Menopause & HRT Matt McKenna Elliot Davis Menopause Before age 40: Premature Menopause After 12 months clinical diagnosis made Depletion of Ovarian Follicles Oestrogen Progesterone LH FSH Spontaneous Amemorrhoea

More information

ZOLADEX 3.6 mg implant SafeSystem Goserelin acetate

ZOLADEX 3.6 mg implant SafeSystem Goserelin acetate ZOLADEX 3.6 mg implant SafeSystem Goserelin acetate Consumer Medicine Information What is in this leaflet This leaflet answers some of the common questions people ask about ZOLADEX 3.6 mg. It does not

More information

CLEAR COVERAGE HYSTERECTOMY CHECKLISTS

CLEAR COVERAGE HYSTERECTOMY CHECKLISTS CLEAR COVERAGE HYSTERECTOMY CHECKLISTS Click on the link below to access the checklist sheet. Abnormal Uterine Bleeding Adenomyosis Chronic Abdominal or Pelvic Pain Endometriosis Fibroids General Guidelines

More information

Chapter 3. Renato Seracchioli Mohamed Mabrouk Clarissa Frascà Linda Manuzzi Luca Savelli Stefano Venturoli Fertil Steril Jul; 94(2):

Chapter 3. Renato Seracchioli Mohamed Mabrouk Clarissa Frascà Linda Manuzzi Luca Savelli Stefano Venturoli Fertil Steril Jul; 94(2): Chapter 3 Long-term oral contraceptive pills and postoperative pain management after laparoscopic excision of ovarian endometrioma: a randomized controlled trial Renato Seracchioli Mohamed Mabrouk Clarissa

More information

Research Article. Comparative analysis of Yoga and clomiphene in infertile women. Richa Sharma 1, Himsweta Shrivastava 1, Arvind Kumar 2

Research Article. Comparative analysis of Yoga and clomiphene in infertile women. Richa Sharma 1, Himsweta Shrivastava 1, Arvind Kumar 2 Research Article Comparative analysis of Yoga and clomiphene in infertile women Richa Sharma 1, Himsweta Shrivastava 1, Arvind Kumar 2 1 Department of Obstetrics & Gynecology, University College of Medical

More information

Ovarian Response to Gonadotrophin Stimulation in Patients with Previous Endometriotic Cystectomy

Ovarian Response to Gonadotrophin Stimulation in Patients with Previous Endometriotic Cystectomy Ovarian Response to Gonadotrophin Stimulation in Patients with Previous Endometriotic Cystectomy M.E. Coccia, F. Cammilli, L. Ginocchini, F. Borruto* and F. Rizzello Dept Gynaecology Perinatology and Human

More information

Summary A LOOK AT ELAGOLIX FOR ENDOMETRIOSIS JULY 2018

Summary A LOOK AT ELAGOLIX FOR ENDOMETRIOSIS JULY 2018 JULY 2018 WHAT IS ENDOMETRIOSIS? Endometriosis is a chronic gynecological condition with symptoms that include painful menstrual periods, nonmenstrual pelvic pain, and pain during intercourse, as well

More information

This case represents 1 of the challenges of

This case represents 1 of the challenges of OBG MANAGEMENT BY DAVID ADAMSON, MD Minimal to mild endometriosis: 4 treatment options Since even limited disease can cause infertility or substantial pain, it should be taken as seriously as severe endometriosis.

More information

Ovaries: In Sickness and Health. Mr N Pisal Consultant Gynaecologist The Portland Hospital

Ovaries: In Sickness and Health. Mr N Pisal Consultant Gynaecologist The Portland Hospital Ovaries: In Sickness and Health Mr N Pisal Consultant Gynaecologist The Portland Hospital Topics for discussion How to assess ovarian function? AMH PCOS Ovarian pain Ovarian cysts Ovarian screening Menopause

More information

Impact of Ovarian Endometrioma Per Se and Surgery on Ovarian Reserve and Pregnancy Rate in in Vitro Fertilization Cycles

Impact of Ovarian Endometrioma Per Se and Surgery on Ovarian Reserve and Pregnancy Rate in in Vitro Fertilization Cycles 1 st SEUD Meeting, 9 May 2015, Paris, France Impact of Ovarian Endometrioma Per Se and Surgery on Ovarian Reserve and Pregnancy Rate in in Vitro Fertilization Cycles ENDOMETRIOSIS ovarian endometrioma

More information

Endometriosis. A Guide for Patients PATIENT INFORMATION SERIES

Endometriosis. A Guide for Patients PATIENT INFORMATION SERIES Endometriosis A Guide for Patients PATIENT INFORMATION SERIES Published by the American Society for Reproductive Medicine under the direction of the Patient Education Committee and the Publications Committee.

More information

Effects of TX-001HR on Uterine Bleeding Rates in Menopausal Women with Vasomotor Symptoms

Effects of TX-001HR on Uterine Bleeding Rates in Menopausal Women with Vasomotor Symptoms Effects of TX-001HR on Uterine Bleeding Rates in Menopausal Women with Vasomotor Symptoms Photo (compulsory) Steven R Goldstein, MD 1 ; Ginger D Constantine, MD 2 ; David F Archer, MD 3 ; James H Pickar,

More information

When acute therapies of menstrually

When acute therapies of menstrually PREVENTIVE TREATMENT OF MENSTRUALLY RELATED MIGRAINE * Stephen D. Silberstein, MD, FACP ABSTRACT Preventive treatment of menstrually related migraine (MRM) is initiated when acute therapies fail to provide

More information

HRT in Perimenopausal Women. Dr. Rubina Yasmin Asst. Prof. Medicine Dhaka Dental College

HRT in Perimenopausal Women. Dr. Rubina Yasmin Asst. Prof. Medicine Dhaka Dental College HRT in Perimenopausal Women Dr. Rubina Yasmin Asst. Prof. Medicine Dhaka Dental College 1 This is the Change But the CHANGE is not a disease 2 Introduction With a marked increase in longevity, women now

More information

Ovarian response in three consecutive in vitro fertilization cycles

Ovarian response in three consecutive in vitro fertilization cycles FERTILITY AND STERILITY VOL. 77, NO. 4, APRIL 2002 Copyright 2002 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Ovarian response in

More information

HORMONES AND YOUR HEALTH Charlie Tucker Pharm. D

HORMONES AND YOUR HEALTH Charlie Tucker Pharm. D HORMONES AND YOUR HEALTH Charlie Tucker Pharm. D All of the hormones in your body are designed to work together. This is God s plan. Therefore, if one is altered, or deficient, it will affect the actions

More information

Addressing Endometriosis with Your Patients: Combining Individualized Treatment Options with Patient-Clinician Dialogue

Addressing Endometriosis with Your Patients: Combining Individualized Treatment Options with Patient-Clinician Dialogue Addressing Endometriosis with Your Patients: Combining Individualized Treatment Options with Patient-Clinician Dialogue Objectives Describe the multiple symptoms of endometriosis and its varied presentation

More information

Fixed Schedule for in vitro Fertilization and Embryo Transfer: Comparison of Outcome between the Short and the Long Protocol

Fixed Schedule for in vitro Fertilization and Embryo Transfer: Comparison of Outcome between the Short and the Long Protocol Yamanashi Med. J. 14(3), 77 ~ 82, 1999 Original Article Fixed Schedule for in vitro Fertilization and Embryo Transfer: Comparison of Outcome between the Short and the Long Protocol Tsuyoshi KASAI and Kazuhiko

More information

Infertility: failure to conceive within one year of unprotected regular sexual intercourse. Primary secondary

Infertility: failure to conceive within one year of unprotected regular sexual intercourse. Primary secondary Subfertility Infertility: failure to conceive within one year of unprotected regular sexual intercourse. Primary secondary Infertility affects about 15 % of couples. age of the female. Other factors that

More information

By J. Jayasutha Lecturer Department of Pharmacy Practice SRM College of Pharmacy SRM University

By J. Jayasutha Lecturer Department of Pharmacy Practice SRM College of Pharmacy SRM University By J. Jayasutha Lecturer Department of Pharmacy Practice SRM College of Pharmacy SRM University Cessation of menstruation as a result of the aging process of or surgical removal of the ovaries; change

More information

What s New in Adolescent Contraception?

What s New in Adolescent Contraception? What s New in Adolescent Contraception? Abby Furukawa, MD Legacy Medical Group Portland Obstetrics and Gynecology April 29, 2017 Objectives Provide an update on contraception options for the adolescent

More information

Hysteroscopic Endometrial Destruction, Optimum Method for Preoperative Endometrial Preparation: A Prospective, Randomized, Multicenter Evaluation

Hysteroscopic Endometrial Destruction, Optimum Method for Preoperative Endometrial Preparation: A Prospective, Randomized, Multicenter Evaluation SCIENTIFIC PAPER Hysteroscopic Endometrial Destruction, Optimum Method for Preoperative Endometrial Preparation: A Prospective, Randomized, Multicenter Evaluation O. Shawki, MD, A. Peters, DO, S. Abraham-Hebert,

More information

Endometriosis is diagnosed by the presence of viable,

Endometriosis is diagnosed by the presence of viable, Clinical Expert Series Clinical Management of Endometriosis Tommaso Falcone, MD, and Rebecca Flyckt, MD Endometriosis is a common and challenging condition of reproductive-aged women that carries a high

More information

Ovarian response after laparoscopic ovarian cystectomy for endometriotic cysts in 132 monitored cycles

Ovarian response after laparoscopic ovarian cystectomy for endometriotic cysts in 132 monitored cycles FERTILITY AND STERILITY VOL. 72, NO. 2, AUGUST 1999 Copyright 1999 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Ovarian response after

More information

Drug Class Update: Drugs for Endometriosis

Drug Class Update: Drugs for Endometriosis Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-2596

More information